ClinicalTrials.gg

Program

SAL0140

A development code. Also written as “SAL0140 Tablets”.

Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 2, since Jun 8, 20264 company-led studies, 4 open or runningNext primary completion: Mar 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals44 open or runningphase 2since Jun 8, 2026Jun 17, 2025Mar 1, 2027phase 2 · NCT07654140

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2025First study: phase 1 study in Uncontrolled HypertensionFirst studyNCT07051603 · 82 planned · China
  2. Jun 8, 20263 phase 2 studiesPhase 2 reachedNCT07646535, NCT07647133, NCT07654140

Ahead

  1. Mar 1, 2027Primary completion: phase 2 study in HypertensionNCT07654140
  2. Apr 1, 2027Primary completion: phase 2 study in HyperaldosteronismNCT07646535
  3. Oct 8, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07647133

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07654140Hypertension · China2RecruitingMar 1, 2027252
NCT07647133Renal Insufficiency, Chronic · China2Not yet recruitingOct 8, 2027249
NCT07646535Hyperaldosteronism · China2Not yet recruitingApr 1, 202750
NCT07051603Uncontrolled Hypertension · China1RecruitingJan 202682

How it is read

Names in the registry

  • “SAL0140”, 4 entries
  • “SAL0140 Tablets”, 4 entries

Codes read as this program: SAL0140.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.